BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38066703)

  • 1. Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients.
    Tateishi U; Kimura K; Tsuchiya J; Kano D; Watabe T; Nonomura N; Saito K; Yokoyama K; Yamagiwa K; Adachi T; Kojima Y; Yoshida S; Fujii Y
    Jpn J Clin Oncol; 2024 Mar; 54(3):282-291. PubMed ID: 38066703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 7. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
    Giesel FL; Hadaschik B; Cardinale J; Radtke J; Vinsensia M; Lehnert W; Kesch C; Tolstov Y; Singer S; Grabe N; Duensing S; Schäfer M; Neels OC; Mier W; Haberkorn U; Kopka K; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):678-688. PubMed ID: 27889802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of
    Sprute K; Kramer V; Koerber SA; Meneses M; Fernandez R; Soza-Ried C; Eiber M; Weber WA; Rauscher I; Rahbar K; Schaefers M; Watabe T; Uemura M; Naka S; Nonomura N; Hatazawa J; Schwab C; Schütz V; Hohenfellner M; Holland-Letz T; Debus J; Kratochwil C; Amaral H; Choyke PL; Haberkorn U; Sandoval C; Giesel FL
    J Nucl Med; 2021 Feb; 62(2):208-213. PubMed ID: 32817141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.
    Liu Y; Zhang X; Liu J; Zhang J; Xu B
    Nucl Med Commun; 2022 Jun; 43(6):725-730. PubMed ID: 35560134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Dosimetry and Biodistribution of
    Piron S; De Man K; Van Laeken N; D'Asseler Y; Bacher K; Kersemans K; Ost P; Decaestecker K; Deseyne P; Fonteyne V; Lumen N; Achten E; Brans B; De Vos F
    J Nucl Med; 2019 Dec; 60(12):1736-1742. PubMed ID: 31028165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting
    Suh M; Ryoo HG; Kang KW; Jeong JM; Jeong CW; Kwak C; Cheon GJ
    Korean J Radiol; 2022 Sep; 23(9):911-920. PubMed ID: 35762185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
    Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
    Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administering [
    Eapen RS; Buteau JP; Jackson P; Mitchell C; Oon SF; Alghazo O; McIntosh L; Dhiantravan N; Scalzo MJ; O'Brien J; Sandhu S; Azad AA; Williams SG; Sharma G; Haskali MB; Bressel M; Chen K; Jenjitranant P; McVey A; Moon D; Lawrentschuk N; Neeson PJ; Murphy DG; Hofman MS
    Eur Urol; 2024 Mar; 85(3):217-226. PubMed ID: 37891072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary Evaluation of
    Lee H; Scheuermann JS; Young AJ; Doot RK; Daube-Witherspoon ME; Schubert EK; Fillare MA; Alexoff D; Karp JS; Kung HF; Pryma DA
    Mol Imaging Biol; 2022 Oct; 24(5):710-720. PubMed ID: 35349040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.